{"schema_version":"1","generated_at":"2026-10-28T11:23:10.032Z","data_as_of":null,"url":"https://www.findmykol.com/kol/neil-palmisiano","json_url":"https://www.findmykol.com/kol/neil-palmisiano/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"neil-palmisiano","name":"Neil Palmisiano","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Philadelphia","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1306007505","orcid":"0000-0003-1524-8108","openalex":"A5050068696"},"summary":"Neil Palmisiano is an Oncology physician. OpenAlex indexes 187 publications with 1,664 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":187,"cited_by_count":1664,"h_index":24,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT03504644","title":"Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia","phase":"PHASE1/PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"ECOG-ACRIN Cancer Research Group","source_url":"https://clinicaltrials.gov/study/NCT03504644","trial_url":"https://www.findmykol.com/trial/NCT03504644"}],"source":"trials"},"payments":{"company_count":12,"program_years":{"first":2021,"last":null},"rows_total":16,"shown":3,"withheld":13,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":1640,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1306007505"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":1038,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1306007505"},{"payer":"BeOne Medicines USA, Inc.","program_year":2025,"amount_usd":129.11,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1306007505"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1306007505","source":"payments"},"prescribing":{"data_year":2024,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":90.1,"classes_total":4,"classes":[{"class":"Nucleoside Metabolic Inhibitor","setting":"prescribed","share_pct":35.3,"drugs":[{"name":"Azacitidine","share_pct":51.7},{"name":"Inqovi","share_pct":22.9},{"name":"Decitabine","share_pct":13.6},{"name":"Onureg","share_pct":11.9}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":29.3,"drugs":[{"name":"Sprycel","share_pct":37.8},{"name":"Tasigna","share_pct":27.6},{"name":"Imatinib Mesylate","share_pct":22.4},{"name":"Bosulif","share_pct":12.2}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":6.3,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":6.3,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":13}]},{"area":"Anti-infectives","share_pct":3.6,"classes_total":1,"classes":[{"class":"Azole Antifungal","setting":"prescribed","share_pct":3.6,"drugs":[{"name":"Posaconazole","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"mixed","data_year":2024,"office_pct":49.3,"facility_pct":50.7},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-766","status":"verified"},{"title":"Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-763","status":"verified"},{"title":"Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-764","status":"verified"},{"title":"Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015176","status":"verified"},{"title":"Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia","year":2024,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2024-194827","status":"verified"}],"source":"works"},"contact":{"address_1":"925 CHESTNUT ST","address_2":"SUITE 320A","city":"Philadelphia","state":"PA","zip":"191074216","phone":"215-955-8874","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1306007505","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":13,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-05-03","provider_certified":"2024-05-03","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}